Drugs / rhIGF-1
rhIGF-1
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01253317 | Dec 2010 → Sep 2012 | Rett syndrome | Boston Children's Hospital | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00516386 | Mar 2007 → May 2008 | anorexia nervosa | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00001669 | Jul 1997 → Apr 2000 | multiple sclerosis | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT01406444 Comparator | Oct 2011 → May 2019 | anorexia nervosa, osteoporosis | Massachusetts General Hospital | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rhIGF-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01253317 ↗ |
| Known as | CEP-151 | “The drug rhIGF-1 (CEP-151) has been shown to play a key role preclinically in oligodendrocyte differentiation and survival” NCT00001669 ↗ |
| Known as | IGF-1 | “using a medication known as IGF-1 (mecasermin or INCRELEX)” NCT01253317 ↗ |
| Modality | Protein / enzyme biologic | “administered recombinant human (rh) rhIGF-1” NCT00516386 ↗ |
| Route | Subcutaneous | “Subcutaneously Administered Insulin-Like Growth Factor-1” NCT00001669 ↗ |